Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis

Mauro Viganò, Massimo Colombo, Adriana Aroldi, Giovanna Lunghi, Elena Manenti, Claudio Ponticelli, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis. Methods: Seventeen such patients [median age: 45 years; 7 with hepatitis B e antigen (HBeAg)] received daily oral doses of 75-150 mg lamivudine for a median of 48 (range 11-81) months. All patients had baseline serum levels of HBV DNA of over 6 log 10 copies per ml and of alanine transaminase (ALT) of over 1.5 times the upper normal limit (UNL). Clinical lamivudine resistance was defined as a rebound of serum HBV DNA above 5.3 log 10 copies per ml and of serum ALT of over 1.5 times the UNL in patients who initially responded with HBV DNA levels of less than 5.3 log 10 copies per ml and normal ALT values. Controls were 14 renal-transplant patients (median age 44 years; 3 with HBeAg) with HBV-related cirrhosis, naive to any anti-HBV therapy, followed for 58 months (4-135). Results: Thirteen (77%) treated patients had a persistent response throughout the study period, including three (18%) who developed genotypic resistance, compared with none of the untreated controls (77% versus 0%, P

Original languageEnglish
Pages (from-to)709-713
Number of pages5
JournalAntiviral Therapy
Volume10
Issue number6
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis'. Together they form a unique fingerprint.

Cite this